The estimated Net Worth of Carole J Uhrich is at least $1.72 Milione dollars as of 13 December 2018. Carole Uhrich owns over 4,110 units of Baxter International stock worth over $548,131 and over the last 21 years Carole sold BAX stock worth over $1,168,152.
Carole has made over 21 trades of the Baxter International stock since 2008, according to the Form 4 filled with the SEC. Most recently Carole exercised 4,110 units of BAX stock worth $163,701 on 13 December 2018.
The largest trade Carole's ever made was exercising 11,749 units of Baxter International stock on 3 December 2018 worth over $484,411. On average, Carole trades about 2,366 units every 97 days since 2003. As of 13 December 2018 Carole still owns at least 13,958 units of Baxter International stock.
You can see the complete history of Carole Uhrich stock trades at the bottom of the page.
Carole's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney e Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: